Neuralstem, Inc., a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, has announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischaemic stroke.
Neuralstem announced the positive top-line results of Phase 1 stroke study in the 2018 ISSCR (International Society for Stem Cell Research) abstract on June 23, 2018.
“The Phase 2 study, which will be a randomised, double-blind, controlled study, is based on the encouraging results from the open-label Phase 1 safety study. It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralysed,” said Karl Johe, Chief Scientific Officer of Neuralstem.
The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on August 1, 2018. Managing the trial will be James Li, Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, a wholly owned subsidiary of Neuralstem, Inc., located in Suzhou, China. Li has been made the Manager and a Registered Agent of Suzhou Neuralstem.
Neuralstem will be allocating US$3 million toward this trial.